Event-Driven Stocks

AMICUS THERAPEUTICS, INC.

FOLD

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 4 good● 2 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$634.2M$528.3M$399.4M$329.2M$305.5M$260.9M
Operating income$32.8M$24.9M−$77.2M−$212.1M−$206.4M−$247.0M
Net income−$27.1M−$56.1M−$151.6M−$236.6M−$250.5M−$276.9M
Total assets$949.9M$785.0M$777.9M$724.2M$905.1M$886.5M
Total liabilities$675.6M$591.0M$617.7M$601.1M$597.8M$600.1M
Equity$274.2M$194.0M$160.2M$123.0M$307.4M$286.4M
EPS (diluted)$-0.09$-0.18$-0.51$-0.82$-0.92$-1.07
Shares out.300.1M295.4M282.7M280.0M264.3M257.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
5.2%
Net margin
−4.3%
Return on equity
−9.9%
Return on assets
−2.9%
Return on capital (ROCE)
4.6%
Liabilities / assets
71.1%
Debt / equity
2.46×
Book value / share
$0.91
Revenue growth (YoY)
20.0%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-5.81distress
Accruals / assets
−6.3%clean
Beneish M-Score
-2.69normal
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
65
/ 100
Profitability 40Growth 100Catalyst 33Earnings quality 100Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 2 warning● 4 good
  • Altman Z″ in the distress zone
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Operating margin is positive
  • Revenue is growing year-over-year
  • Positive operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Apr 15, 202621.9M7.5+3.9%
Mar 31, 202621.1M5.7+4.5%
Mar 13, 202620.2M5.5+6.3%
Feb 27, 202619.0M6.2+7.6%
Feb 13, 202617.6M2.2-1.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)